[Form 4] CONMED Corp Insider Trading Activity

Rhea-AI Filing Summary

CONMED Corp (CNMD) director Charles Farkas reported two open-market sales totaling 2,000 shares on 09/12/2025. The filings show a sale of 1,103 shares at $53.535 and a sale of 897 shares at $53.512. The beneficial ownership reported after the transactions is shown as 15,756 shares and 14,859 shares on the respective lines. The Form 4 is signed by Thomas Fistek on behalf of Mr. Farkas by power of attorney on 09/15/2025.

Positive

• Timely and complete SEC disclosure of insider sales with prices and share counts provided
• Form filed by power of attorney and signed, indicating procedural compliance

Negative

• Director sold a total of 2,000 shares (1,103 at $53.535 and 897 at $53.512) on 09/12/2025
• Post-transaction beneficial ownership decreased as shown by the reported holdings (15,756 and 14,859 shares) on the filing lines

Insights

Financial Analyst

TL;DR: Director disposition of 2,000 CNMD shares via two sales on 09/12/2025; transaction amounts and post-sale holdings disclosed.

The Form 4 documents two separate sales executed the same day: 1,103 shares at $53.535 and 897 shares at $53.512, totaling 2,000 shares sold. The reporting lines list the beneficial ownership following each transaction as 15,756 and 14,859 shares respectively. The disclosure is straightforward and provides price and share counts necessary for tracking insider activity but does not include context such as proceeds or intent. For investors, this is a routine insider sale disclosure rather than evidence of company-level events.

Corporate Governance Expert

TL;DR: Filing shows compliance with Section 16 reporting; signature executed by PoA on 09/15/2025.

The Form 4 identifies Charles Farkas as a director and indicates the report was filed by one reporting person. The signature block shows Thomas Fistek signed on behalf of Mr. Farkas by power of attorney, dated 09/15/2025, which meets standard practice when principals delegate filing authority. There are no derivative transactions or additional disclosures of plans; this appears to be a routine change in beneficial ownership requiring public disclosure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farkas Charles

(Last) (First) (Middle)

C/O CONMED CORPORATION

11311 CONCEPT BOULEVARD

(Street)

LARGO FL 33773

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CONMED Corp [ CNMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/12/2025		S		1,103	D	$53.535	15,756	D
Common Stock	09/12/2025		S		897	D	$53.512	14,859	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Thomas Fistek for Charles Farkas by Power of Attorney	09/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CONMED (CNMD) report on this Form 4?

The Form 4 reports two open-market sales by director Charles Farkas on 09/12/2025: 1,103 shares at $53.535 and 897 shares at $53.512, totaling 2,000 shares sold.

How much beneficial ownership did Charles Farkas have after the sales?

The filing lists beneficial ownership following the reported transactions as 15,756 shares on one line and 14,859 shares on the subsequent line.

Who signed the Form 4 for Charles Farkas?

The Form 4 was signed by Thomas Fistek on behalf of Charles Farkas by power of attorney, dated 09/15/2025.

Were there any derivative transactions reported by the insider?

No derivative securities are reported in Table II; the Form 4 only discloses non-derivative common stock sales.

Does the filing indicate the reason for the sales or a planned trading arrangement?

The filing does not state a reason for the sales and does not indicate that the transactions were made pursuant to a Rule 10b5-1 plan.